O	0	7	Effects
O	8	10	of
O	11	12	a
B-intervention	13	21	Plantago
I-intervention	22	27	ovata
I-intervention	27	28	-
I-intervention	28	33	based
I-intervention	34	40	herbal
I-intervention	41	49	compound
O	50	52	in
O	53	63	prevention
O	64	67	and
O	68	77	treatment
O	78	80	of
B-condition	81	85	oral
I-condition	86	95	mucositis
O	96	98	in
O	99	107	patients
O	108	112	with
O	113	119	breast
O	120	126	cancer
O	127	136	receiving
O	137	149	chemotherapy
O	149	150	:
O	151	152	A
O	153	159	double
O	159	160	-
O	160	165	blind
O	165	166	,
O	167	177	randomized
O	177	178	,
O	179	189	controlled
O	190	199	crossover
O	200	205	trial
O	205	206	.

O	207	211	Oral
O	212	221	mucositis
O	222	223	(
O	223	225	OM
O	225	226	)
O	227	229	is
O	230	233	one
O	234	236	of
O	237	240	the
O	241	245	most
O	246	252	common
O	253	266	complications
O	267	269	of
O	270	279	mucotoxic
O	280	286	cancer
O	287	294	therapy
O	294	295	.

O	296	305	Mucositis
O	306	313	induces
O	314	324	clinically
O	325	336	significant
O	337	341	pain
O	341	342	,
O	343	352	increases
O	353	356	the
O	357	361	risk
O	362	364	of
O	365	375	infections
O	376	379	and
O	380	387	affects
O	388	391	the
O	392	400	patients
O	400	401	'
O	402	409	quality
O	410	412	of
O	413	417	life
O	417	418	.

O	419	423	This
O	424	429	study
O	430	442	investigated
O	443	446	the
O	447	454	effects
O	455	457	of
O	458	460	an
O	461	467	herbal
O	468	479	preparation
O	480	484	from
O	485	493	Plantago
O	494	499	ovata
O	500	512	hydrocolloid
O	513	515	in
O	516	519	the
O	520	530	prevention
O	531	534	and
O	535	544	treatment
O	545	547	of
O	548	550	OM
O	550	551	,
O	552	554	in
B-eligibility	555	561	breast
I-eligibility	562	568	cancer
I-eligibility	569	577	patients
I-eligibility	578	588	undergoing
I-eligibility	589	601	chemotherapy
I-eligibility	602	606	with
I-eligibility	607	608	a
I-eligibility	609	616	regimen
I-eligibility	617	626	including
I-eligibility	627	637	adriamycin
O	637	638	.

O	639	643	This
O	644	652	research
O	653	656	was
O	657	658	a
O	659	665	double
O	665	666	-
O	666	671	blind
O	671	672	,
O	673	683	randomized
O	683	684	,
O	685	695	controlled
O	696	705	crossover
O	706	711	trial
O	711	712	.

O	713	716	The
O	717	723	herbal
O	724	732	compound
O	733	742	consisted
O	743	745	of
O	746	747	a
O	748	755	mixture
O	756	758	of
O	759	762	500
O	763	765	mg
O	766	768	of
O	769	770	P
O	770	771	.
O	772	777	ovate
O	778	782	husk
O	783	785	in
O	786	788	30
O	789	791	mL
O	792	797	water
O	798	802	plus
O	803	808	three
O	809	814	drops
O	815	817	of
O	818	825	vinegar
O	826	829	per
O	830	834	dose
O	834	835	,
O	836	841	which
O	842	845	was
O	846	850	used
O	851	853	as
O	854	855	a
O	856	865	mouthwash
O	865	866	.

O	867	880	Phytochemical
O	881	884	and
O	885	900	physicochemical
O	901	906	tests
O	907	909	of
O	910	913	the
O	914	922	compound
O	923	927	were
O	928	932	also
O	933	942	performed
O	942	943	.

B-total-participants	944	950	Twenty
I-total-participants	950	951	-
I-total-participants	951	956	eight
B-eligibility	957	965	patients
I-eligibility	966	969	who
I-eligibility	970	979	developed
I-eligibility	980	989	mucositis
I-eligibility	990	996	during
I-eligibility	997	1000	the
I-eligibility	1001	1013	chemotherapy
I-eligibility	1014	1023	screening
I-eligibility	1024	1029	cycle
O	1030	1034	were
O	1035	1045	randomized
O	1046	1048	to
O	1049	1052	the
O	1053	1059	herbal
O	1060	1068	compound
O	1069	1070	(
O	1070	1071	n
O	1072	1073	=
B-intervention-participants	1074	1076	14
O	1076	1077	)
O	1078	1081	and
B-control	1082	1089	placebo
O	1090	1091	(
O	1091	1092	n
O	1093	1094	=
B-control-participants	1095	1097	14
O	1097	1098	)
O	1099	1105	groups
O	1105	1106	.

O	1107	1111	They
O	1112	1120	received
O	1121	1127	herbal
O	1128	1136	compound
O	1137	1139	or
O	1140	1147	placebo
O	1148	1153	three
O	1154	1159	times
O	1160	1163	per
O	1164	1167	day
O	1168	1174	during
O	1175	1180	their
O	1181	1185	next
O	1186	1198	chemotherapy
O	1199	1204	cycle
O	1205	1206	(
O	1206	1211	cycle
O	1212	1213	1
O	1214	1216	of
O	1217	1226	treatment
O	1226	1227	)
O	1227	1228	.

O	1229	1237	Patients
O	1238	1242	were
O	1243	1250	crossed
O	1251	1255	over
O	1256	1262	during
O	1263	1268	cycle
O	1269	1270	2
O	1271	1273	of
O	1274	1283	treatment
O	1284	1287	and
O	1288	1296	received
O	1297	1300	the
O	1301	1312	alternative
O	1313	1320	therapy
O	1320	1321	.

O	1322	1324	An
O	1325	1329	oral
O	1330	1334	care
O	1335	1343	protocol
O	1344	1347	was
O	1348	1358	prescribed
O	1359	1361	to
O	1362	1365	all
O	1366	1374	patients
O	1375	1377	in
O	1378	1384	cycles
O	1385	1386	1
O	1387	1390	and
O	1391	1392	2
O	1393	1395	of
O	1396	1399	the
O	1400	1409	treatment
O	1409	1410	.

O	1411	1414	The
O	1415	1423	patients
O	1424	1428	were
O	1429	1436	visited
O	1437	1439	at
O	1440	1448	baseline
O	1448	1449	,
O	1450	1453	the
O	1454	1457	end
O	1458	1460	of
O	1461	1464	the
O	1465	1470	first
O	1471	1474	and
O	1475	1481	second
O	1482	1487	weeks
O	1488	1490	of
O	1491	1494	the
O	1495	1504	screening
O	1505	1510	cycle
O	1510	1511	,
O	1512	1515	and
O	1516	1519	the
O	1520	1523	end
O	1524	1526	of
O	1527	1530	the
O	1531	1536	first
O	1537	1540	and
O	1541	1547	second
O	1548	1553	weeks
O	1554	1556	of
O	1557	1561	each
O	1562	1564	of
O	1565	1568	two
O	1569	1578	treatment
O	1579	1585	cycles
O	1585	1586	.

O	1587	1590	The
O	1591	1597	degree
O	1598	1600	of
O	1601	1610	mucositis
O	1611	1614	was
O	1615	1619	used
O	1620	1622	as
O	1623	1626	the
O	1627	1631	main
O	1632	1641	treatment
O	1642	1649	outcome
O	1649	1650	.

O	1651	1656	Other
O	1657	1664	indexes
O	1664	1665	,
O	1666	1670	such
O	1671	1673	as
O	1674	1677	the
O	1678	1686	severity
O	1687	1689	of
O	1690	1694	pain
O	1694	1695	,
O	1696	1706	xerostomia
O	1707	1712	grade
O	1713	1716	and
O	1717	1720	the
O	1721	1728	quality
O	1729	1731	of
O	1732	1736	life
O	1737	1741	were
O	1742	1746	also
O	1747	1755	measured
O	1755	1756	.

O	1757	1765	Compared
O	1766	1770	with
O	1771	1774	the
O	1775	1782	placebo
O	1782	1783	,
O	1784	1787	the
O	1788	1794	herbal
O	1795	1803	compound
O	1804	1817	significantly
O	1818	1825	reduced
O	1826	1829	the
B-outcome	1830	1836	degree
I-outcome	1837	1839	of
I-outcome	1840	1849	mucositis
O	1849	1850	,
O	1851	1854	the
B-outcome	1855	1863	severity
I-outcome	1864	1866	of
I-outcome	1867	1871	pain
O	1872	1875	and
O	1876	1879	the
B-outcome	1880	1890	xerostomia
I-outcome	1891	1896	grade
O	1896	1897	;
O	1898	1900	it
O	1901	1905	also
O	1906	1914	improved
O	1915	1918	the
O	1919	1927	patients
O	1927	1928	'
O	1929	1936	quality
O	1937	1939	of
O	1940	1944	life
O	1945	1946	(
O	1946	1947	P
O	1948	1949	<
O	1950	1951	0
O	1951	1952	.
O	1952	1954	05
O	1954	1955	)
O	1955	1956	.

O	1957	1967	Comparison
O	1968	1975	between
O	1976	1979	the
O	1980	1989	screening
O	1990	1995	cycle
O	1996	1999	and
O	2000	2007	placebo
O	2008	2017	treatment
O	2018	2023	group
O	2024	2030	showed
O	2031	2035	that
O	2036	2039	the
O	2040	2044	oral
O	2045	2049	care
O	2050	2058	protocol
O	2059	2062	had
O	2063	2064	a
O	2065	2076	significant
O	2077	2083	effect
O	2084	2086	in
O	2087	2090	the
O	2091	2100	reduction
O	2101	2103	of
B-outcome	2104	2106	OM
O	2107	2108	(
O	2108	2109	P
O	2110	2111	<
O	2112	2113	0
O	2113	2114	.
O	2114	2116	05
O	2116	2117	)
O	2117	2118	.

O	2119	2122	The
O	2123	2127	oral
O	2128	2132	care
O	2133	2141	protocol
O	2142	2145	and
O	2146	2149	the
O	2150	2156	herbal
O	2157	2165	compound
O	2166	2171	based
O	2172	2174	on
O	2175	2176	P
O	2176	2177	.
O	2178	2183	ovata
O	2184	2187	are
O	2188	2197	effective
O	2198	2202	ways
O	2203	2206	for
O	2207	2217	preventing
O	2218	2221	and
O	2222	2230	treating
O	2231	2233	OM
O	2234	2236	in
O	2237	2245	patients
O	2246	2256	undergoing
O	2257	2266	mucotoxic
O	2267	2273	cancer
O	2274	2281	therapy
O	2281	2282	.

O	2283	2290	Iranian
O	2291	2299	registry
O	2300	2302	of
O	2303	2311	clinical
O	2312	2318	trials
O	2319	2339	IRCT20180923041093N1
O	2339	2340	.
